PHNM Stock Overview
A pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Pharmanutra S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €62.60 |
| 52 Week High | €69.60 |
| 52 Week Low | €51.70 |
| Beta | 0.26 |
| 11 Month Change | 0% |
| 3 Month Change | 2.96% |
| 1 Year Change | -12.08% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -11.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHNM | GB Personal Products | GB Market | |
|---|---|---|---|
| 7D | 0% | 3.4% | 2.2% |
| 1Y | -12.1% | 21.0% | 8.0% |
Return vs Industry: PHNM underperformed the UK Personal Products industry which returned -5.9% over the past year.
Return vs Market: PHNM underperformed the UK Market which returned -2.4% over the past year.
Price Volatility
| PHNM volatility | |
|---|---|
| PHNM Average Weekly Movement | n/a |
| Personal Products Industry Average Movement | 4.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: PHNM has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHNM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 90 | Roberto Lacorte | www.pharmanutra.it |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, Africa, Far East, and internationally. It also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. The company’s products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Cetilar Tape, Cetilar Oro, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2.
Pharmanutra S.p.A. Fundamentals Summary
| PHNM fundamental statistics | |
|---|---|
| Market cap | €522.13m |
| Earnings (TTM) | €14.05m |
| Revenue (TTM) | €93.22m |
37.2x
P/E Ratio5.6x
P/S RatioIs PHNM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHNM income statement (TTM) | |
|---|---|
| Revenue | €93.22m |
| Cost of Revenue | €48.64m |
| Gross Profit | €44.59m |
| Other Expenses | €30.54m |
| Earnings | €14.05m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.46 |
| Gross Margin | 47.83% |
| Net Profit Margin | 15.07% |
| Debt/Equity Ratio | 52.8% |
How did PHNM perform over the long term?
See historical performance and comparison